Correction: The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis

Estarreja, JoãoMendes, PriscilaSilva, CarinaCamacho, PedroMateus, Vanessa2023-12-172023-12-172023-12Estarreja J, Mendes P, Silva C, Camacho P, Mateus V. Correction: The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis. JMIR Res Protoc. 2023;12:e50411.http://hdl.handle.net/10400.21/16721[This corrects the article DOI: 10.2196/38658.]engOphthalmologyAge-related macular degenerationBevacizumabDrug therapynAMDNeovascular age-related macular degenerationWet macular degenerationCorrection: The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysisjournal article10.2196/50411